Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
Alan S. Coates(International Breast Cancer Study Group), Binghe Xu(Chinese Academy of Medical Sciences & Peking Union Medical College), Andrew Tutt(Institute of Cancer Research), Jacek Jassem(Gdańsk Medical University), Emiel J. Rutgers(Oncode Institute), Monica Castiglione‐Gertsch(University of Geneva), Fátima Cardoso(Breast Cancer Alliance), Michael Gnant(Austrian Breast & Colorectal Cancer Study Group), Viviana Galimberti, Nadia Harbeck(Breast Center), Bent Ejlertsen, Ian Smith(Queensland Health), C. Kent Osborne(Texas Oncology), Ann H. Partridge(Dana-Farber Cancer Institute), Richard D. Gelber(Harvard University), Nancy E. Davidson(WinnMed), Clifford A. Hudis(American Society of Clinical Oncology), Kathleen I. Pritchard, Marco Colleoni(European Institute of Oncology), Felix Sedlmayer, Roberto Orecchia(Istituti di Ricovero e Cura a Carattere Scientifico), Harold J. Burstein(Dana-Farber Cancer Institute), Hervé Bonnefoi, Pamela J. Goodwin(Lunenfeld-Tanenbaum Research Institute), Beat Thürlimann(University of St.Gallen), Jens Huober(University of St.Gallen), Semiglazov Vf(Institute of Oncology NN Petrov), Daniel F. Hayes(University of Michigan–Ann Arbor), Eric P. Winer(University of Vermont), John Forbes(University of Limerick), Jonas Bergh(Karolinska Institutet), Zefei Jiang, Monica Morrow(Memorial Sloan Kettering Cancer Center), Zhi‐Ming Shao(Fudan University Shanghai Cancer Center), James N. Ingle(Mayo Clinic), Martine Piccart(Université Libre de Bruxelles), Per Karlsson(University of Gothenburg), Masakazu Toi(Mukogawa Women's University), Angelo Di Leo(Hospital of Prato), Lorena de la Peña, H.-J. Senn(Breast Center), Fabrice André(Inserm), Aron Goldhirsch(Istituti di Ricovero e Cura a Carattere Scientifico), Giuseppe Curigliano(European Institute of Oncology), José Baselga(Novartis (Switzerland))
Cited by 1,836
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Reduction of Maternal-Infant Transmission of Human Immunodeficiency Virus Type 1 with Zidovudine Treatment
|New England Journal of Medicine|1994|3.7k
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
|Annals of Oncology|2013|3.7k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k